{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:05:12Z","timestamp":1789131912946,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaad.2024.12.041","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T19:48:47Z","timestamp":1737575327000},"page":"1039-1048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interferon-\u03b1 biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: A monocentric study of 184 patients"],"prefix":"10.1016","volume":"92","author":[{"given":"Quitterie","family":"Murat de Montai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Masseran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Perray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Dorgham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Gorochov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Teboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Franc\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Barbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Charre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-8607","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Chasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9957","key":"10.1016\/j.jaad.2024.12.041_bib1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2024.12.041_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866319","article-title":"A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus","volume":"13","author":"Curtiss","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The european working party on systemic lupus erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jaad.2024.12.041_bib4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2018.06.040","article-title":"Natural history of disease activity and damage in patients with cutaneous lupus erythematosus","volume":"79","author":"Ker","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2022.03.056","article-title":"Prevalence and factors associated with long-term remission in cutaneous lupus: a longitudinal cohort study of 141 cases","volume":"87","author":"Fayard","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2022.01.052","article-title":"Discoid lesions and smoking history are negative predictors of disease activity remission in cutaneous lupus erythematosus","volume":"87","author":"Florez-Pollack","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.12.041_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2021.07.038","article-title":"Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: a retrospective multicenter cohort study of 56 patients","volume":"87","author":"Sonigo","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.12.041_bib8","first-page":"1785","article-title":"Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent","volume":"33","author":"Neogi","year":"2006","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.12.041_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2024.12.041_bib10","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3899\/jrheum.100007","article-title":"Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome","volume":"37","author":"Steiman","year":"2010","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.12.041_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13075-017-1442-6","article-title":"Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review","volume":"19","author":"Gensous","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.jaad.2024.12.041_bib13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0961203310371161","article-title":"The interferon-\u03b1 signature of systemic lupus erythematosus","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.jaad.2024.12.041_bib14","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/jir.2011.0071","article-title":"Interferon alpha as a primary pathogenic factor in human lupus","volume":"31","author":"Niewold","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.jaad.2024.12.041_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jaad.2024.12.041_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.12.041_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.jaad.2024.12.041_bib18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/jcm8081244","article-title":"Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes","volume":"8","author":"Berthier","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2133.2012.10825.x","article-title":"The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score","volume":"166","author":"Braunstein","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib20","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.jaad.2024.12.041_bib21","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/ard.2008.093146","article-title":"Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus","volume":"68","author":"Landolt-Marticorena","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital Enzyme-Linked Immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.12.041_bib23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2024.12.041_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","article-title":"The classification and diagnosis of cutaneous lupus erythematosus","volume":"48-49","author":"Kuhn","year":"2014","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.12.041_bib26","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","article-title":"Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus","volume":"147","author":"Klein","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.12.041_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1365-2133.2011.10693.x","article-title":"Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome","volume":"166","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.12.041_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/ar4111","article-title":"Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus","volume":"14","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2021.08.036","article-title":"Preliminary definition of flare in cutaneous lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index","volume":"87","author":"Keyes","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.12.041_bib31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaad.2022.09.028","article-title":"Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients","volume":"88","author":"Fredeau","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5475","key":"10.1016\/j.jaad.2024.12.041_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/251543a0","article-title":"Pronounced antiviral activity of human interferon on bovine and porcine cells","volume":"251","author":"Gresser","year":"1974","journal-title":"Nature"},{"issue":"2-3","key":"10.1016\/j.jaad.2024.12.041_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0022-510X(88)90125-6","article-title":"Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy","volume":"84","author":"Lebon","year":"1988","journal-title":"J Neurol Sci"},{"issue":"14","key":"10.1016\/j.jaad.2024.12.041_bib35","first-page":"1135","article-title":"[Herpes encephalitis in adults and interferon (author's transl)]","volume":"10","author":"Vezinet","year":"1981","journal-title":"Nouv Presse Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0961203320967759","article-title":"Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus","volume":"30","author":"Hu","year":"2021","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.jaad.2024.12.041_bib37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaad.2021.04.032","article-title":"Elevated serum levels of C-X-C motif chemokine ligand 10 can distinguish systemic lupus erythematosus patients from cutaneous lupus erythematosus patients","volume":"85","author":"Zhu","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.12.041_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm-20-5232","article-title":"Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.12.041_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archderm.1982.01650180046015","article-title":"Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients","volume":"118","author":"Callen","year":"1982","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.12.041_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2133.2009.09472.x","article-title":"Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients","volume":"162","author":"Vera-Recabarren","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.12.041_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/biom13020367","article-title":"Complement as a biomarker for systemic lupus erythematosus","volume":"13","author":"Ayano","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaad.2024.12.041_bib42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jaad.2024.12.041_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:12:52Z","timestamp":1762261972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0190962225001112"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.12.041","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b1 biological activity is associated with disease activity and risk of flare in cutaneous lupus erythematosus: A monocentric study of 184 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.12.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}